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Abstract: Cell-free DNA (cfDNA) quantity and quality in plasma has been investigated as a
non-invasive biomarker in cancer. Previous studies have demonstrated increased cfDNA amount
and length in different types of cancer with respect to healthy controls. The present study aims to test
the hypothesis that the presence of longer DNA strands circulating in plasma can be considered a
biomarker for tumor presence in thyroid cancer. We adopted a quantitative real-time PCR (qPCR)
approach based on the quantification of two amplicons of different length (67 and 180 bp respectively)
to evaluate the integrity index 180/67. Cell-free DNA quantity and integrity were higher in patients
affected by nodular thyroid diseases than in healthy controls. Importantly, cfDNA integrity index
was higher in patients with cytological diagnosis of thyroid carcinoma (Thy4/Thy5) than in subjects
with benign nodules (Thy2). Therefore, cfDNA integrity index 180/67 is a suitable parameter for
monitoring cfDNA fragmentation in thyroid cancer patients and a promising circulating biomarker
in the diagnosis of thyroid nodules.
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1. Introduction
Cancer-derived DNA in blood represents a promising biomarker for cancer diagnosis. Previous
studies have demonstrated an increase of cell-free circulating DNA in different types of cancer [1] in
comparison to the general population.
Even if it is well known that DNA concentration in plasma is elevated in cancer patients [1]
and can be influenced by tumor characteristics [2], the hypotheses on its origin are still controversial
and details on the mechanism of release are not completely disclosed [3]. Circulating free-DNA is
released from apoptotic or necrotic cells, reflecting a differential DNA origin. Necrosis is common in
solid malignant cancers and generates a spectrum of DNA fragments of different size, due to random
digestion by DNases. In contrast, cell death in normal blood nucleated cells occurs mostly via apoptosis
that generates small and uniform DNA fragments. Support for this hypothesis has been reported
by several papers [2,4–12] and confirmed in recent studies demonstrating increased DNA length in
plasma from patients with breast [13,14], prostate [15], colorectal [16–18] and lung cancer [19].
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In addition, total cell-free DNA (cfDNA) concentration may also be altered in patients with
various benign diseases such as trauma, stroke, burns, sepsis, and autoimmune diseases, thus limiting
its value for diagnosis of cancer [20]. For this reason, the simple cell-free DNA quantitative analysis
cannot provide the expected clinical specificity.
To this purpose, the search of qualitative alterations of DNA, such as mutations, loss of
heterozygosity (LOH), microsatellite instability and epigenetic changes, were shown to improve
the cancer specificity [2]. Tumor biomarkers identified in plasma of cancer patients may have a high
diagnostic and prognostic value, however, the detection of these alterations is limited by the frequency
of their occurrence in each tumor type and their tumor-specificity so that the development of different
assays can be necessary when dealing with tumors with different mutational signatures.
Our attention is focused on fragmentation of plasma DNA. We extensively studied the
characteristics of cfDNA in plasma of melanoma patients, evidencing that total quantity and integrity
index could provide useful information to discriminate the tumor affected population from healthy
individuals [9]. The test is based on the hypothesis that DNA fragments in plasma are longer than
those of healthy individuals on account of an inefficient nuclease activity.
This manuscript studies patients affected by differentiated papillary thyroid carcinoma to test
the hypothesis that the presence of longer DNA strands circulating in plasma can be considered
a biomarker for tumor presence also in the case of thyroid cancer. We adopted a qPCR approach
based on the quantification of two amplicons of different length (67 and 180 bp respectively) to
evaluate the integrity index 180/67 whose performance had been previously evaluated in a case study
composed of melanoma patients. Control subjects and subjects affected by benign pathologies have
been considered as the references. Our aim is to investigate the ability of this parameter to provide
diagnostic information related to the cytomorphological classification of this tumor performed on fine
needle aspirates (FNA) of the nodular lesion.
2. Results
2.1. Plasma DNA Concentration and Integrity in Basal Blood Samples
Total cfDNA was quantified by the qPCR assay targeting the 67 bp amplicon on the APP gene
(see Methods section). Quantitative values of cfDNA concentration in plasma are reported in Table 1
and graphically represented in Figure 1a. Patients affected by nodular thyroid diseases (respectively
Thy2, Thy3 and Thy4/Thy5 cytology) showed higher levels of total cfDNA than healthy individuals
(p < 0.001).
Table 1. Quantitative values of cell-free DNA (cfDNA) markers in the case study.
(cfDNA) (ng/mL pl) App 180 (ng/mL pl) Integrity Index 180/67
Healthy n = 49 Median 5.12 2.42 0.56
Range 0.99–26.71 0.40–12.68 0.08–1.81
Thy2 n = 25 Median 11.88 9.03 0.67
Range 5.10–296.52 4.55–261.04 0.22–1.24
Thy3 n = 44 Median 12.41 9.02 0.83
Range 2.26–128.44 0.20–199.07 0.01–2.21
Thy4 + Thy5 n = 28 Median 11.47 10.15 1.02
Range 1.31–62.60 2.19–82.65 0.22–2.02
Analogously, cfDNA quantity according to the qPCR assay targeting the 180 bp amplicon on the
APP gene (see Methods section) was constantly higher in each patient’s cytology group (Thy2, Thy3
and Thy4/Thy5) than healthy controls with a p value lower than 0.001. The results are reported in
Table 1 and Figure 1b.
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Figure 1. Box plots reflecting the distribution in cases (Thy2, Thy3 and Thy4/Thy5) and controls 
(healthy subjects) of total cfDNA quantity (a), and cfDNA quantity according to a qPCR assay 
targeting a 180 bp amplicon on the APP gene (b). Each box indicates the 25th and 75th percentiles. 
The horizontal line inside the box indicates the median, and the whiskers indicate the extreme 
measured values. Dots and stars represent outliers. 
Cell-free DNA integrity assessed by means of the integrity index 180/67 (see Methods section) 
was significantly higher in Thy2 (p = 0.01), Thy3 (p = 0.002) and Thy4/Thy5 (p < 0.001) patients than 
control subjects. 
Subjects affected by benign thyroid nodules (Thy2) showed an integrity index significantly 
lower (p = 0.013) than that found in patients with cytological diagnosis of thyroid cancer 
(Thy4/Thy5). 
The values of integrity index for each patient’s group are reported in Table 1 and Figure 2. 
We did not find any significant difference in cfDNA quantity and integrity stratifying patients 
on the basis of sex and age. 
 
Figure 2. Cell-free DNA integrity in the categories of the case study: healthy subjects, Thy2, Thy3 and 
Thy4/Thy5. Box plots indicate the 25th and 75th percentiles. The horizontal line inside the box 
indicates the median, and the whiskers indicate the extreme measured values. Dots represent 
outliers. 
Figure 1. Box plots reflecting the distribution in cases (Thy2, Thy3 and Thy4/Thy5) and controls
(healthy subjects) of total cfDNA quantity (a), and cfDNA quantity according to a qPCR assay targeting
a 180 bp amplicon on the APP gene (b). Each box indicates the 25th and 75th percentiles. The horizontal
line inside the box indicates the median, and the whiskers indicate the extreme measured values. Dots
and stars represent outliers.
Cell-free DNA integrity assessed by means of the integrity index 180/67 (see Methods section)
was significantly higher in Thy2 (p = 0.01), Thy3 (p = 0.002) and Thy4/Thy5 (p < 0.001) patients than
control subjects.
Subjects affected by benign thyroid nodules (Thy2) showed an integrity index significantly lower
(p = 0.013) than that found in patients with cytological diagnosis of thyroid cancer (Thy4/Thy5).
The values of integrity index for each patient’s group are reported in Table 1 and Figure 2.
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Figure 2. Cell-free DNA integrity in the categories of the case study: healthy subjects, Thy2, Thy3
and Thy4/Thy5. Box plots indicate the 25th and 75th percentiles. The horizontal line inside the box
indicates the median, and the whiskers indicate the extreme measured values. Dots represent outliers.
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We did not find any significant difference in cfDNA quantity and integrity stratifying patients on
the basis of sex and age.
2.2. cfDNA Fragments
The absolute concentration of cfDNA fragments with length ranging from 67 to 180 bp, calculated
by subtracting the absolute concentration of the longer amplicon from that of the shorter one, was
significantly lower in Thy4/Thy5 patients (median = −0.12, range −20.05–28.62) than subjects with
Thy2 nodules (median = 3.40, range −2.24–47.94, p = 0.010) and healthy controls (median = 2.22, range
−1.98–14.16, p = 0.013).
Alternatively, the percentage of cfDNA fragments between 67 and 180 bp was calculated by
subtracting the absolute concentration of the longer amplicon to that of the shorter one and normalizing
for total cfDNA quantity (assessed by the shorter amplicon).
Healthy controls presented about 44% of these fragments, with a significant difference with
respect to Thy2 (33%, p = 0.010), Thy3 (17%, p = 0.002) and Thy4/Thy5 (−2%, p < 0.001) patients.
Thy2 subjects showed a higher percentage of fragments between 67 and 180 bp than Thy4/Thy5
patients (p = 0.013).
2.3. Plasma DNA Integrity in Post-Surgery Blood Samples
The specificity of the assay was demonstrated considering the variation of plasma DNA
concentration and integrity from the pre-surgery value to that found after treatment, few months later.
Specifically, for a group of 17 patients, an additional blood draw was taken 3–6 months after surgery
and radioactive iodine treatment when appropriate.
While no statistical differences were evidenced, independently from the amplicon length, between
pre-surgery total cell-free DNA concentration and that found at the follow-up time, the after surgery
sample showed a lower integrity index (median = 0.59, range 0.36–1.67) than that taken before surgery
(median = 0.87, range 0.32–1.30, p = 0.035, Figure 3).
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After surgery, thyroid cancer patients showed a higher percentage of small (67–180 bp)
DNA fragments (median = 41.02 range −30.28–67.87) in comparison to the pre-surgery condition
(median = 12.99 range −67.18–64.00, p = 0.035).
2.4. ROC (Receiver Operating Characteristic) Curve Analysis
The predictive capability (i.e., diagnostic performance) of cfDNA quantity and integrity in thyroid
cancer was investigated by means of the area under the ROC curve by comparing healthy subjects
with patients with cytological diagnosis of thyroid carcinoma (Thy4/Thy5).
All the three markers showed a good predictive capability with an area under the ROC curve
(AUC) of 0.765 (p < 0.001), 0.982 (p < 0.001) and 0.796 (p < 0.001) for cfDNA quantity by 67 bp amplicon,
cfDNA quantity by 180 bp amplicon and integrity index, respectively (Figure 4).
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Figure 4. Receiver Operating Characteristic (ROC) curve of cfDNA quantity assessed by two qPCR
assays targeting respectively a 67 and a 180 bp amplicon on the APP gene and cfDNA integrity index
180/67 in patients with cytological diagnosis of thyroid carcinoma (Thy4/Thy5) and control subjects.
ROC curve analysis was also used to investigate the diagnostic performance of the markers under
study by comparing Thy2 subjects with Thy4/Thy5 patients. Among the three considered parameters,
only cfDNA integrity showed a good AUC (0.699) with a significant p value (p = 0.013).
3. Discussion
Assays performed on tumor surrogate samples are attractive mainly because of limited
invasiveness of sample collection. CfDNA determination may represent an affordable way to impact
on a potential diagnostic, prognostic and monitoring tool in oncology.
Notwithstanding a presumed lack of specificity of the simple estimation of the quantity and
quality of total cfDNA, our previous results in melanoma patients show that, by jointly considering
a panel of four biomarkers including two tumor-specific ones, the highest predictive capability was
given by total cfDNA followed by integrity index 180/67 [21].
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Thus, the aim of the present work was to study cfDNA quantity and the qualitative parameter
integrity index 180/67 in thyroid cancer patients; to date, the latter aspect has not been investigated.
The study focused on the quantitative determination of circulating DNA by means of two qPCR
assays differing in the amplicon length (67 and 180 bp respectively).
It is generally accepted that the 180 bp-fragment reflects apoptosis, which is the prevalent
mechanism of cell death in normal cells, while necrosis, producing much longer DNA fragments,
seems to occur more frequently in tumor cells [22,23].
A statistically significant increase could be evidenced in nodular goiter patients when compared to
healthy subjects for both the absolute measurements of DNA concentration and the deriving integrity
index, similarly to already published results for different types of cancer. In fact, notwithstanding
a great heterogeneity in the pre-analytical and analytical steps, most of the papers based on qPCR
approaches to measure DNA fragmentation in plasma report an increase of integrity index in tumor
patients in comparison to the healthy population [6,7,10,13–19].
Besides qPCR, other approaches such as electrophoresis, electron and atomic force microscopy
and, more recently, massive parallel sequencing have been adopted for the determination of
cfDNA fragment size [5], providing insights into different aspects of cfDNA. However, among
the above mentioned approaches qPCR represents a fast, reliable and cheap method to investigate
cfDNA integrity.
The most relevant result in our study is the significant difference in cfDNA integrity index between
subjects with benign nodules (Thy2) and patients with cytological diagnosis of thyroid carcinoma
(Thy4/Thy5). This finding supports cfDNA integrity as a promising biomarker in the diagnosis of
thyroid nodules.
Another important finding is the significant reduction of the considered integrity index evidenced
3–6 months after surgery. This result could be an indication of successful removal of the tumor,
analogously to what is reported by Gang et al. [24], and demonstrates the relationship between cfDNA
integrity index and tumor presence.
By evaluating the percentage of fragments in the range of length 67–180 bp, we evidenced
differences between the cytological categories of the case study (Thy2, Thy3 and Thy4/Thy5) and
control subjects, and a higher percentage of fragments in subjects with Thy2 nodules with respect to
Thy4/Thy5 patients. Analogously, post-surgical thyroid cancer patients show a higher percentage of
small DNA fragments (67–180 bp) in comparison to the pre-surgery condition. The same fragment
distribution could be evidenced in our previous study on melanoma patients [9] with the smaller
fragment being more abundant in control subjects with respect to melanoma and after tumor removal.
These analogous results confirm that total cfDNA analysis (quantity and quality) can be considered a
tumor-independent marker.
In conclusion, cfDNA integrity index 180/67 turned out to be a suitable parameter for monitoring
cfDNA fragmentation in thyroid cancer patients. These data support the hypothesis that a panel of
circulating biomolecular markers can be a non-invasive, valuable tool in the diagnosis of differentiated
thyroid cancer and are in line with our previous findings on the detection of BRAFV600E mutation in
plasma from patients with this disease [25]. As a perspective in thyroid patients, further studies using
DNA integrity index to monitor patients’ outcome and the effect of therapy are advisable. Moreover,
based on our previous experience in melanoma, a multimarker approach, taking into account different
biomarkers related to both cfDNA quantity and quality [21], as well as markers of tumor origin, should
be pursued.
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4. Materials and Methods
4.1. Patients
The presence of cfDNA circulating in plasma and its integrity features were evaluated in
97 patients (71 females and 26 males, age range 18–90 years, median 56 years) admitted to the
Endocrinology Unit of Careggi Teaching Hospital because of nodular goiter between 2011 and 2015.
Patients were submitted to US-FNA according to the adopted guidelines [26] and the cytological
diagnoses were made in accordance with the five diagnostic groups of the British Thyroid Association,
2007: Thy 1—non-diagnostic; Thy 2—non-neoplastic, Thy 3—follicular lesions, Thy 4—suspicious
of malignancy, Thy 5—diagnostic of malignancy [27]. When more than 1 nodule was sampled by
US-FNA in multinodular goiters, the worst cytology was considered.
Our case study is composed as follows: Thy2 (n = 25), Thy3 (n = 44), Thy4 (n = 24) and Thy5
(n = 4).
Seventeen patients affected by PTC were submitted to a second blood draw 3–6 months after
surgery (mean 4.4 months, range 2.7–6.4 months). In this period of time, 12 patients also underwent
radioactive iodine (RAI) treatment according to the adopted guidelines [28,29].
Healthy subjects were used as control populations, (n = 49, 26 females and 23 males, age range
25–89 years, median 53 years).
The research protocol was conducted in accordance with the guidelines in the Declaration of
Helsinki and approved by the local review board “Comitato Etico Regione Toscana Sezione Area Vasta
Centro” (code: CEAVC BIO 16.026, 2017); all the patients signed an informed consent.
4.2. DNA Extraction
Peripheral blood (5 mL) was collected in an ethylenediaminetetraacetic acid (EDTA) tube,
transported within one hour to the laboratory and centrifuged twice at 4 ◦C for 10 min (1600 and 14,000
rcf). Plasma aliquots were stored at −80 ◦C before use. DNA was extracted from 2 mL of plasma,
using the QIAsymphony Circulating DNA Kit (Qiagen, Hilden, Germany).
4.3. Plasma DNA Integrity Index 180/67 by qPCR
The quantity and integrity of the cell-free DNA circulating in plasma was evaluated by a
quantitative real-time PCR (qPCR) targeting the human APP (Amyloid Precursor protein, chr. 21q21.2)
gene (accession NM_000484). The assays were designed in a way that the forward primer and the
probe were the same for all amplicons, whereas the reverse primer varied (see ref. [9] for sequences and
qPCR protocol). The lengths of the amplicons selected for this study were 67 and 180 bps respectively.
Absolute quantification of the shorter amplicon (67 bp) on the gene APP was performed in plasma
samples to accurately measure the amount of free circulating DNA per mL plasma, using primers
and probe previously reported [30]. This assay was assumed to be able to measure the total amount
of circulating plasma DNA, including fragments down to 67 bp of length. Quantification of DNA
concentration was obtained by interpolation on an external reference curve ranging from 10 to 105
pg/reaction of genomic DNA. (A DNA preparation obtained by Sigma-Aldrich was employed as
the standard).
The ratio between the absolute concentration of the longer amplicon (180 bp) and the shorter
one (67 bp) defined the integrity index 180/67, which was used to assess the fragmentation of cfDNA.
Higher integrity index values indicate that all the cfDNA molecules are at least 180 bp in length in the
APP gene. Lower integrity indexes mean that cfDNA contains fragments below 180 bp in the same
target sequence.
4.4. Statistical Analysis
Statistical analysis was carried out using the SPSS statistics software package version 24 (IBM,
Armonk, NY, USA). Quantitative results were evaluated by Mann–Whitney and Wilcoxon signed-rank
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test. p values lower than 0.05 were considered statistically significant. The predictive capability
(i.e., diagnostic performance) of each biomarker was investigated by means of the area under the
ROC (Receiver-Operating Characteristics) curve (AUC). The ROC curve measures the accuracy of
biomarkers when their expression is detected on a continuous scale, displaying the relationship
between sensitivity (true-positive rate, y-axes) and 1-specificity (false-positive rate, x-axes) across
all possible threshold values of the considered biomarker. A useful way to summarize the overall
diagnostic accuracy of the biomarker is the area under the ROC curve (AUC), the value of which is
expected to be 0.5 in the absence of predictive capability, whereas it tends to be 1.00 in the case of high
predictive capacity [31].
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